Is Bax/Bcl-2 Ratio Considered As a Prognostic Marker with Age and Tumor Location in Colorectal Cancer?

Overview

Journal Iran Biomed J

Specialties Biology
General Medicine

Date 2015 Apr 14

PMID 25864810

Citations 81

Authors

Ehsan Khodapasand

Narges Jafarzadeh

Farid Farrokhi

Behnam Kamalidehghan

Massoud Houshmand

Affiliations

Soon will be listed here.

Abstract

Background: Bax and Bcl-2 are the major members of Bcl-2 family whose play a key role in tumor progression or inhibition of intrinsic apoptotic pathway triggered by mitochondrial dysfunction. Therefore, the balance between pro- and anti-apoptotic members of this family can determine the cellular fate.

Methods: In this study, the relative level of mRNA expression of Bax and Bcl-2 genes was determined using RNA extraction, cDNA synthesis and RT-qPCR technique from 22 tumoral tissues and adjacent non-tumoral tissues from adenocarcinoma colorectal cancer.

Results: The potential prognostic and predictive significance of Bax and Bcl-2 gene expression and Bax/Bcl-2 ratio were demonstrated in colorectal cancer. The significant correlation between qPCR data and different clinicopathologic parameters of colorectal carcinoma, including age, gender, tumor size, tumor stage, tumor location, and tumor differentiation was also examined. Interestingly, no significant correlation was seen between Bax and Bcl-2 expressions and clinicopathological parameters of colorectal cancer. However, Bax/Bcl-2 ratio was statistically correlated with age and tumor location. Patients with age above 50 showed decreased levels of Bax/Bcl-2 ratio. Moreover, the Bax/Bcl-2 ratio was significantly lower in tumors resected from colon compared to sigmoid colon, rectosigmoid and rectum tumors.

Conclusion: This study indicates a significant correlation between age and tumor location with Bax/Bcl-2 expression ratio, suggesting predictive value as a potential molecular marker of colorectal cancer.

Citing Articles

Phenylbutyric Acid Modulates Apoptosis and ER Stress-Related Gene Expression in Glycogen Storage Disease Type Ib In Vitro Model.

Parezanovic M, Stevanovic N, Andjelkovic M, Ugrin M, Pavlovic S, Stojiljkovic M Mol Genet Genomic Med. 2025; 13(1):e70054.

PMID: 39803753 PMC: 11726116. DOI: 10.1002/mgg3.70054.

Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy.

cinakova A, Vavrincova-Yaghi D, Krenek P, Klimas J, Kralova E Sci Rep. 2025; 15(1):1464.

PMID: 39789116 PMC: 11718164. DOI: 10.1038/s41598-024-84487-w.

Rhodium complex [RhLI]I: a novel anticancer agent inducing tumor inhibition and apoptosis.

Hossain M, Soha K, Rahman A, Auwal A, Pronoy T, Rashel K Discov Oncol. 2024; 15(1):782.

PMID: 39692939 PMC: 11655795. DOI: 10.1007/s12672-024-01632-7.

Optimization of Antiproliferative Properties of Triimine Copper(II) Complexes.

Choroba K, Zowislok B, Kula S, Machura B, Maron A, Erfurt K J Med Chem. 2024; 67(21):19475-19502.

PMID: 39496093 PMC: 11571215. DOI: 10.1021/acs.jmedchem.4c01806.

The molecular anti-metastatic potential of CBD and THC from Lebanese Cannabis via apoptosis induction and alterations in autophagy.

Younes M, Hage M, Shebaby W, Al Toufaily S, Ismail J, Naim H Sci Rep. 2024; 14(1):25642.

PMID: 39463375 PMC: 11514238. DOI: 10.1038/s41598-024-76340-x.

References

Paul-Samojedny M, Kokocinska D, Samojedny A, Mazurek U, Partyka R, Lorenz Z . Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis. Biochim Biophys Acta. 2005; 1741(1-2):25-9. DOI: 10.1016/j.bbadis.2004.11.021. View

Haggar F, Boushey R . Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2010; 22(4):191-7. PMC: 2796096. DOI: 10.1055/s-0029-1242458. View

Tsamandas A, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatsoris T . Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome. In Vivo. 2007; 21(1):113-8. View

Paradiso A, Simone G, Lena M, Leone B, Vallejo C, Lacava J . Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer. 2001; 84(5):651-8. PMC: 2363782. DOI: 10.1054/bjoc.2000.1658. View

Bufill J . Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990; 113(10):779-88. DOI: 10.7326/0003-4819-113-10-779. View

Wray C, Ziogas A, Hinojosa M, Le H, Stamos M, Zell J . Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009; 52(8):1359-66. DOI: 10.1007/DCR.0b013e3181a7b7de. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Jansson A, Sun X . Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol. 2002; 20(3):811-6. DOI: 10.1200/JCO.2002.20.3.811. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

10.

Sun N, Meng Q, Tian A . Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. Am J Surg. 2010; 200(3):341-5. DOI: 10.1016/j.amjsurg.2009.10.024. View

11.

Katkoori V, Suarez-Cuervo C, Shanmugam C, Jhala N, Callens T, Messiaen L . Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2012; 1(2):76-89. PMC: 3397579. DOI: 10.3978/j.issn.2078-6891.2010.019. View

12.

Packham G . Mutation of BCL-2 Family Proteins in Cancer. Apoptosis. 2003; 3(2):75-82. DOI: 10.1023/a:1009688706783. View

13.

Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, Collan Y . Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology. 2003; 64(4):435-42. DOI: 10.1159/000070304. View

14.

Nehls O, Okech T, Hsieh C, Enzinger T, Sarbia M, Borchard F . Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007; 96(9):1409-18. PMC: 2360187. DOI: 10.1038/sj.bjc.6603728. View

15.

Hemminki K, Santi I, Weires M, Thomsen H, Sundquist J, Lorenzo Bermejo J . Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer. 2010; 10:688. PMC: 3022888. DOI: 10.1186/1471-2407-10-688. View

16.

Zhao D, Ding X, Peng J, Zheng Y, Zhang S . Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B. 2005; 6(12):1163-9. PMC: 1390638. DOI: 10.1631/jzus.2005.B1163. View

17.

Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, Yuan-Yuan G . Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem. 2011; 113(8):810-4. DOI: 10.1016/j.acthis.2011.01.002. View

18.

Raisova M, Hossini A, Eberle J, Riebeling C, Wieder T, Sturm I . The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol. 2001; 117(2):333-40. DOI: 10.1046/j.0022-202x.2001.01409.x. View

19.

Sturm I, Kohne C, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S . Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999; 17(5):1364-74. DOI: 10.1200/JCO.1999.17.5.1364. View

20.

Yip K, Reed J . Bcl-2 family proteins and cancer. Oncogene. 2008; 27(50):6398-406. DOI: 10.1038/onc.2008.307. View